PCV13i is an improved pneumococcal conjugate vaccine being developed by us, 13-valent vaccine primarily used for the prevention of invasive pneumococcal diseases. 

We are also developing a potential China best-in-class PCV13. Currently, PPV23 products are the primary pneumococcal vaccines in China, in contrast with most developed countries where PCV13 products are predominantly used. Compared with Prevnar 13 and other PCV13 candidates, our PCV13i incorporates key improvements in conjugate design and manufacturing processes. As a result, our PCV13i has shown better immunogenicity than Prevnar 13 in pre-clinical studies. We plan to file the CTA for our PCV13i candidate by the end of 2018.